SUNNYVALE, Calif., April 5 /PRNewswire/ -- American Peptide Company (APC) announced today that it has entered into a manufacturing clinical supply agreement with Affymax, Inc. for the current Good Manufacturing Practices (cGMP) production of the Affymax drug candidate Hematide(TM). A synthetic, peptide-based, next-generation erythropoiesis-stimulating agent (ESA), Hematide is designed to stimulate the production of red blood cells. It is being evaluated by Affymax in Phase 2 clinical trials to treat anemia in patients with chronic kidney disease (CKD) and cancer. APC had previously successfully manufactured preclinical lots of Hematide for Affymax and will manufacture clinical supplies of Hematide at its large-scale cGMP manufacturing facility near San Diego, Calif.
“The addition of Affymax to our customer roster is a testament to our expertise in synthesizing high-quality peptides for clinical trials for pharmaceutical and biotech companies worldwide,” said Jim Hampton, vice president of business development for APC. “We have extensive experience manufacturing peptides under cGMP regulations at our state-of-the art facility. We are pleased to be working with Affymax to manufacture its promising synthetic peptide for the treatment of anemia.”
About American Peptide Company, Inc. (APC)
American Peptide Company is a leading manufacturing partner for peptides and peptide conjugates. APC offers comprehensive selections of pre-manufactured catalog peptides in convenient aliquots, a complete spectrum of custom synthesis services from array screens to mg and kg of research-grade peptides, and full-scale cGMP manufacturing of pharmaceutical-grade peptides for clinical trials. APC is experienced in solid-phase and solution-phase peptide synthesis and organic conjugations to proteins, toxoids, antifungals and PEG under cGMP. As a wholly-owned subsidiary of Itoham Foods, Inc. of Japan with offices in the U.S., Japan and China, APC remains dedicated to delivering high-quality peptides to pharmaceutical and biotech companies worldwide. More information can be obtained at www.americanpeptide.com.
About Affymax
Affymax, Inc. is a clinical-stage pharmaceutical company that is developing a rich pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer. Hematide(TM), the Company’s first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. Currently, it is in Phase 2 trials for the treatment of anemia associated with chronic kidney disease and cancer. For more information go to www.affymax.com.
American Peptide Company
CONTACT: Jim Hampton, VP of Business Development of American PeptideCompany, +1-408-733-7604
